Update in Precision Oncology in Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Update in Precision Oncology in Non-small Cell Lung Cancer

Published:2024-02-28 Issue:1 Volume:4 Page:
ISSN:2770-3533
Container-title:International Journal of Cancer Care and Delivery
language:en
Short-container-title:

Author:

Riano Ivy¹,Abuali Inas²,Abrams Hannah³,Khan Moiz⁴,Adjei Alex A⁵,Neal Joel⁶,Das Millie⁷

Affiliation:

1. Dartmouth Cancer Center, Hanover, NH, USA

2. Mass General Cancer Center, Boston, MA, USA

3. Fred Hutchinson Cancer Center, Seattle, WA, USA

4. Karmanos Cancer Institute, Detroit, MI, USA

5. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

6. Stanford Cancer Institute, Palo Alto, CA, USA

7. Palo Alto VA Health Care System, Palo Alto, CA, USA

Abstract

Treatments for lung cancer have historically been considered “one-size-fits-all” The development of Precision Oncology, however, has led to increased recognition of non-small cell lung cancer (NSCLC) as a molecularly complex amalgam of diseases with differing outcomes. The 2023 Precision Oncology Summit was held in San Francisco on October 7th and 8th, focused on actionable strategies addressing personalized treatment to improve outcomes of patient with lung cancer. This manuscript summarizes the discussion and key learning points from the precision medicine clinical science symposium in NSCLC, including the latest translational science, and clinical applications updates.

Publisher

Binaytara Foundation

Reference17 articles.

1. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002);A. Inoue;Annals of Oncology,2013

2. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC;Suresh S. Ramalingam;New England Journal of Medicine,2020

3. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations;News release. FDA,2018

4. Osimertinib in resected EGFR-mutated non–small-cell lung cancer;Jie He;New England Journal of Medicine,2020

5. FDA approves first adjuvant therapy for most common type of lung cancer;News release. FDA,2020